Latest Thermogenesis (KOOL) Headlines
Cesca Therapeutics Appoints Dr. Mahendra Rao to Board of Directors
GlobeNewswire - Mon Mar 03, 8:15AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., today announced that Dr. Mahendra Rao has been appointed to the Company's board of directors effective April 1, 2014. His appointment brings the Company's number of directors to six.
Cesca Therapeutics and Cook Medical Enter Supply Agreement for a Phase 1b Clinical Trial
GlobeNewswire - Mon Feb 24, 8:00AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., announced today that they have entered a supply agreement with Cook Medical.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Cesca Therapeutics Inc., Formerly ThermoGenesis Corp., Closes Merger With TotipotentRX Corporation and Changes Name
GlobeNewswire - Wed Feb 19, 6:30AM CST
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) ("Company") (Nasdaq:KOOL) today announced that it consummated the merger with TotipotentRX Corporation ("TotipotentRX") for approximately 12,490,800 shares of the Company's common stock, as contemplated by the previously announced Agreement and Plan of Reorganization (the "Merger Agreement").
ThermoGenesis Corp. Reports Second Quarter Fiscal 2014 Results
GlobeNewswire - Fri Feb 14, 3:00PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the second quarter of fiscal 2014.
ThermoGenesis Corp. Stockholders Approve Acquisition of TotipotentRX
GlobeNewswire - Thu Feb 13, 12:50PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, reported today that it received stockholder approval at a special meeting of the stockholders for the acquisition of TotipotentRX through a merger into ThermoGenesis. Incident to the acquisition, ThermoGenesis will also change its corporate name to Cesca Therapeutics Inc., which stands for Clinical Excellence in Stem Cell Applications.
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2014 Results on February 14, 2014
GlobeNewswire - Tue Feb 11, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal second quarter ended December 31, 2013, on Friday, February 14, 2014.
DeNA Reports Third Quarter, Fiscal Year 2013 Financial Results
GlobeNewswire - Wed Feb 05, 12:04AM CST
DeNA Co., Ltd. (Tokyo:2432), the global leader in mobile Internet services, today announced its financial results for the quarter ended December 31, 2013. DeNA reported quarterly revenue of 41.7 billion yen (408 million* USD), 20 percent lower than the same quarter last year, and operating profit of 11.4 billion yen (112 million* USD), 42 percent lower than the same quarter of the previous year.
TotipotentRX and ThermoGenesis Achieve Bone Marrow Stem Cell Transplant Milestone
GlobeNewswire - Mon Feb 03, 8:20AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease, announced the TotiPotentRX cellular therapy clinical team in partnership with Fortis Healthcare, Gurgaon (New Delhi) has achieved its 20 pediatric bone marrow transplant (BMT). This haploidentical BMT was performed from a mother as a donor for a 10 year old child suffering from combined immunodeficiency due to a DOCK-8 gene mutation. The Fortis Centre has so far performed 15 allogenetic BMT including five haploidentical and one double unrelated cord blood transplants, and 5 autologous transplants. This transplant was completed on February 1, 2014 at the Pediatric Hematology and Bone Marrow Transplant department led by Dr. Satya Yadav, M.D., Head of the Department for Pediatric Hematology and Bone Marrow Transplant, and with scientific and laboratory support by the TotipotentRX's cell therapy GMP laboratory facility. This 20 transplant is a significant milestone in the pursuit of developing the new FMRI BMT program into one of the leading stem cell transplant centers in Asia.
ThermoGenesis Corp. Raises $6.67 Million in Private Placement Financing
GlobeNewswire - Mon Jan 27, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) today announced that it has entered into definitive agreements with institutional investors in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, ThermoGenesis will receive gross proceeds of approximately $6.67 million resulting from the issuance and sale of approximately 3.33 million shares of common stock at a price per share of $2.00. The purchasers will also receive warrants to purchase up to approximately 1.66 million shares of common stock at an exercise price of $2.81 per share. The warrants are non-exercisable for six months after the closing of the financing and have a term of 5 years.
Most active Nasdaq-traded stocks
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Nasdaq stocks posting largest volume increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
TotipotentRX Corporation and ThermoGenesis Corp. Report Statistically Significant Phase Ib Clinical Trial Results in Critical Limb Ischemia
GlobeNewswire - Tue Jan 21, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's CLIRST (Critical Limb Ischemia Rapid Stem cell Therapy) treatment. The companies will host a joint conference call to review the study results in detail on Monday, January 27, 2014 at 2:00pm Pacific (5:00pm Eastern).
ThermoGenesis Signs Direct Supply Agreement With Cord Blood Registry
GlobeNewswire - Wed Jan 08, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced the signing of a five-year agreement to supply Cord Blood Registry (CBR), the world's largest and most experienced newborn stem cell company, with ThermoGenesis' AutoXpress System (AXP) cord blood processing system and disposables. The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems. Previously, ThermoGenesis supplied CBR the AXP System indirectly through its North American independent distributor.
ThermoGenesis Announces Bebevida Agreement
GlobeNewswire - Mon Dec 23, 11:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced it has entered into a long term agreement to provide its AXP AutoXpress System (AXP) to Bebevida, a leading cord blood stem cell bank in Portugal. The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems.
ThermoGenesis Reports First Quarter Fiscal 2014 Results
GlobeNewswire - Thu Nov 14, 3:00PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the first quarter of fiscal 2014.
ThermoGenesis Corp. to Announce First Quarter Fiscal 2014 Results on November 14, 2013
GlobeNewswire - Fri Nov 08, 3:06PM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal first quarter ended September 30, 2013, on Thursday, November 14, 2013.
Cesca Therapeutics Appoints Dr. Mahendra Rao to Board of Directors
GlobeNewswire - Mon Mar 03, 8:15AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., today announced that Dr. Mahendra Rao has been appointed to the Company's board of directors effective April 1, 2014. His appointment brings the Company's number of directors to six.
Cesca Therapeutics and Cook Medical Enter Supply Agreement for a Phase 1b Clinical Trial
GlobeNewswire - Mon Feb 24, 8:00AM CST
Cesca Therapeutics Inc. (Nasdaq:KOOL), formerly known as ThermoGenesis Corp., announced today that they have entered a supply agreement with Cook Medical.
5 Stocks Ready to Skyrocket Higher
at The Street - Wed Feb 19, 1:14PM CST
These stocks are setting up to explode to the upside.
Cesca Therapeutics Inc., Formerly ThermoGenesis Corp., Closes Merger With TotipotentRX Corporation and Changes Name
GlobeNewswire - Wed Feb 19, 6:30AM CST
Cesca Therapeutics Inc. (f/n/a ThermoGenesis Corp.) ("Company") (Nasdaq:KOOL) today announced that it consummated the merger with TotipotentRX Corporation ("TotipotentRX") for approximately 12,490,800 shares of the Company's common stock, as contemplated by the previously announced Agreement and Plan of Reorganization (the "Merger Agreement").
ThermoGenesis Corp. Reports Second Quarter Fiscal 2014 Results
GlobeNewswire - Fri Feb 14, 3:00PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the second quarter of fiscal 2014.
ThermoGenesis Corp. Stockholders Approve Acquisition of TotipotentRX
GlobeNewswire - Thu Feb 13, 12:50PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, reported today that it received stockholder approval at a special meeting of the stockholders for the acquisition of TotipotentRX through a merger into ThermoGenesis. Incident to the acquisition, ThermoGenesis will also change its corporate name to Cesca Therapeutics Inc., which stands for Clinical Excellence in Stem Cell Applications.
ThermoGenesis Corp. to Announce Second Quarter Fiscal 2014 Results on February 14, 2014
GlobeNewswire - Tue Feb 11, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal second quarter ended December 31, 2013, on Friday, February 14, 2014.
DeNA Reports Third Quarter, Fiscal Year 2013 Financial Results
GlobeNewswire - Wed Feb 05, 12:04AM CST
DeNA Co., Ltd. (Tokyo:2432), the global leader in mobile Internet services, today announced its financial results for the quarter ended December 31, 2013. DeNA reported quarterly revenue of 41.7 billion yen (408 million* USD), 20 percent lower than the same quarter last year, and operating profit of 11.4 billion yen (112 million* USD), 42 percent lower than the same quarter of the previous year.
TotipotentRX and ThermoGenesis Achieve Bone Marrow Stem Cell Transplant Milestone
GlobeNewswire - Mon Feb 03, 8:20AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease, announced the TotiPotentRX cellular therapy clinical team in partnership with Fortis Healthcare, Gurgaon (New Delhi) has achieved its 20 pediatric bone marrow transplant (BMT). This haploidentical BMT was performed from a mother as a donor for a 10 year old child suffering from combined immunodeficiency due to a DOCK-8 gene mutation. The Fortis Centre has so far performed 15 allogenetic BMT including five haploidentical and one double unrelated cord blood transplants, and 5 autologous transplants. This transplant was completed on February 1, 2014 at the Pediatric Hematology and Bone Marrow Transplant department led by Dr. Satya Yadav, M.D., Head of the Department for Pediatric Hematology and Bone Marrow Transplant, and with scientific and laboratory support by the TotipotentRX's cell therapy GMP laboratory facility. This 20 transplant is a significant milestone in the pursuit of developing the new FMRI BMT program into one of the leading stem cell transplant centers in Asia.
ThermoGenesis Corp. Raises $6.67 Million in Private Placement Financing
GlobeNewswire - Mon Jan 27, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) today announced that it has entered into definitive agreements with institutional investors in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, ThermoGenesis will receive gross proceeds of approximately $6.67 million resulting from the issuance and sale of approximately 3.33 million shares of common stock at a price per share of $2.00. The purchasers will also receive warrants to purchase up to approximately 1.66 million shares of common stock at an exercise price of $2.81 per share. The warrants are non-exercisable for six months after the closing of the financing and have a term of 5 years.
Most active Nasdaq-traded stocks
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at the close of trading:
Nasdaq stocks posting largest volume increases
AP - Wed Jan 22, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
TotipotentRX Corporation and ThermoGenesis Corp. Report Statistically Significant Phase Ib Clinical Trial Results in Critical Limb Ischemia
GlobeNewswire - Tue Jan 21, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL) a cellular therapy medical device company and TotipotentRX Corporation, a clinical-stage regenerative medicine company developing novel therapies for cardiovascular and orthopedic disease announce their co-sponsored Phase Ib clinical trial safety and efficacy results treating no-option patients suffering from critical limb ischemia with Totipotent's CLIRST (Critical Limb Ischemia Rapid Stem cell Therapy) treatment. The companies will host a joint conference call to review the study results in detail on Monday, January 27, 2014 at 2:00pm Pacific (5:00pm Eastern).
ThermoGenesis Signs Direct Supply Agreement With Cord Blood Registry
GlobeNewswire - Wed Jan 08, 8:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced the signing of a five-year agreement to supply Cord Blood Registry (CBR), the world's largest and most experienced newborn stem cell company, with ThermoGenesis' AutoXpress System (AXP) cord blood processing system and disposables. The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems. Previously, ThermoGenesis supplied CBR the AXP System indirectly through its North American independent distributor.
ThermoGenesis Announces Bebevida Agreement
GlobeNewswire - Mon Dec 23, 11:00AM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today announced it has entered into a long term agreement to provide its AXP AutoXpress System (AXP) to Bebevida, a leading cord blood stem cell bank in Portugal. The AXP System is a proprietary family of automated devices with companion sterile blood processing disposables for harvesting cord blood stem cells in closed systems.
ThermoGenesis Reports First Quarter Fiscal 2014 Results
GlobeNewswire - Thu Nov 14, 3:00PM CST
ThermoGenesis Corp. (Nasdaq:KOOL) ("ThermoGenesis"), a leading supplier of enabling technologies for the processing and storage of stem cells and other biological tissues, today reported financial results for the first quarter of fiscal 2014.
ThermoGenesis Corp. to Announce First Quarter Fiscal 2014 Results on November 14, 2013
GlobeNewswire - Fri Nov 08, 3:06PM CST
ThermoGenesis Corp. (Nasdaq:KOOL), a leading supplier of innovative products that process and store adult stem cells, announced today it will report financial results for the fiscal first quarter ended September 30, 2013, on Thursday, November 14, 2013.
